rimonabant (Acomplia, Zimulti)
Jump to navigation
Jump to search
Introduction
Tradename: Acomplia (withdrawn from European Market in 2009)
Indications
- obesity[2] (see RIO-North America study)
- smoking cessation
- hypercholesterolemia
- diabetes mellitus type 2[5]
Dosage
5-20 mg QD
Adverse effects
Mechanism of action
- selective cannabinoid receptor 1 (CB1) antagonist
- diminishes appetite
- improves lipid profile
- improves glycemic control
- failed to reduce progression of coronary artery disease in patients with metabolic syndrome[8]
More general terms
Additional terms
References
- ↑ Prescriber's Letter 11(11): 2004 Investigational Drug: Rimonabant (Acomplia) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=201114&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Journal Watch 25(12):98, 2005 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16;365(9468):1389-97. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15836887
- ↑ Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121-34. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16291982
- ↑ Prescriber's Letter 13(3): 2006 Acomplia (Rimonabant) and OTC Orlistat for Weight Loss Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220313&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 Sheen AJ et al, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006, 368:1660 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17098084
- ↑ 6.0 6.1 Prescriber's Letter 14(7): 2007 (subscription needed) http://www.prescribersletter.com
- ↑ 7.0 7.1 7.2 Christensen R et al, Efficacy and safety of the weight-loss drug remonant: A meta- analysis of randomised trials. Lancet 2007, 370:1706 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18022033
- ↑ 8.0 8.1 Nissen SE et al, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRDIVARIUS randomized controlled trial. JAMA 2008, 299:1547 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18387931
- ↑ 9.0 9.1 9.2 Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 Nov 17;370(9600):1706-13. Review. Erratum in: Lancet. 2008 Feb 16;371(9612):558. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18022033